tradingkey.logo

Nektar Therapeutics <NKTR.OQ> expected to post a loss of 16 cents a share - Earnings Preview

ReutersMay 6, 2025 9:08 PM
  • Nektar Therapeutics NKTR.OQ NKTR.O is expected to show a fall in quarterly revenue when it reports results on May 8 for the period ending March 31 2025

  • The San Francisco California-based company is expected to report a 29.0% decrease in revenue to $15.357 million from $21.64 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Nektar Therapeutics is for a loss of 16 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Nektar Therapeutics is $5.00​, above​ its last closing price of $0.69. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.18

-0.17

-0.16

Beat

4.9

Sep. 30 2024

-0.22

-0.21

-0.18

Beat

14.6

Jun. 30 2024

-0.21

-0.20

-0.25

Missed

-22.8​

Mar. 31 2024

-0.19

-0.19

-0.19

Met

0

​​Dec. 31 2023

-0.22

-0.21

-0.22

Missed

-3.6

Sep. 30 2023

-0.21

-0.20

-0.24

Missed

-20.3​

Jun. 30 2023

-0.31

-0.28

-0.27

Beat

4.9

Mar. 31 2023

-0.23

-0.25

-0.32

Missed

-26.7

This summary was machine generated May 6 at 21:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI